Is FAS/Fas ligand system involved in equine corpus luteum functional regression? 2010

Antonio M Galvao, and David W Ramilo, and Dariusz J Skarzynski, and Karolina Lukasik, and Angela Tramontano, and Antonio Mollo, and Luisa M Mateus, and Graca Maria L Ferreira-Dias
C.I.I.S.A., Faculty of Veterinary Medicine, Technical University of Lisbon, Lisbon, Portugal.

Proapoptotic factor Fas ligand (FASL) and its cell surface receptor FAS are tumor necrosis factor superfamily members that trigger apoptosis in different cell types. However, their influence on luteal steroidogenesis is not clearly understood. The aim of the present work was to determine (i) the presence of the cytokine FASL and its receptor FAS in the mare's corpus luteum (CL) throughout the luteal phase, as well as (ii) the influence of FASL alone, or together with the cytokines tumor necrosis factor alpha (TNF) and interferon gamma (IFNG), on equine luteal cell production of luteotrophic and luteolytic factors, cell viability, and apoptosis. FASL and FAS protein expression and mRNA transcription were evaluated in different luteal stages of the equine CL by Western blotting and real-time PCR assays, respectively. Protein expression and FASL mRNA transcription increased in the late CL. Also, FAS and FASL proteins were present in large steroidogenic and endothelial CL cells throughout the luteal phase, as demonstrated by immunohistochemistry. Equine luteal cells isolated from midluteal phase CL were stimulated without (control) or with exogenous cytokines: FASL (10 ng/ml); TNF+IFNG (10 ng/ml each; positive control) or FASL+TNF+IFNG (10 ng/ml each). FASL clearly inhibited in vitro progesterone and prostaglandin E(2) (PGE(2)) production by equine luteal cells but increased prostaglandin F(2alpha) (PGF(2alpha)). Furthermore, FASL effect on equine luteal cell viability depended on the presence of cytokines TNF and IFNG. In conclusion, this study shows the presence of FASL and FAS in the equine CL and suggests their importance in functional luteolysis.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D007371 Interferon-gamma The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES. Interferon Type II,Interferon, Immune,gamma-Interferon,Interferon, gamma,Type II Interferon,Immune Interferon,Interferon, Type II
D008183 Luteal Phase The period in the MENSTRUAL CYCLE that follows OVULATION, characterized by the development of CORPUS LUTEUM, increase in PROGESTERONE production by the OVARY and secretion by the glandular epithelium of the ENDOMETRIUM. The luteal phase begins with ovulation and ends with the onset of MENSTRUATION. Menstrual Cycle, Luteal Phase,Menstrual Cycle, Secretory Phase,Menstrual Secretory Phase,Postovulatory Phase,Phase, Luteal,Phase, Postovulatory,Secretory Phase, Menstrual
D011374 Progesterone The major progestational steroid that is secreted primarily by the CORPUS LUTEUM and the PLACENTA. Progesterone acts on the UTERUS, the MAMMARY GLANDS and the BRAIN. It is required in EMBRYO IMPLANTATION; PREGNANCY maintenance, and the development of mammary tissue for MILK production. Progesterone, converted from PREGNENOLONE, also serves as an intermediate in the biosynthesis of GONADAL STEROID HORMONES and adrenal CORTICOSTEROIDS. Pregnenedione,Progesterone, (13 alpha,17 alpha)-(+-)-Isomer,Progesterone, (17 alpha)-Isomer,Progesterone, (9 beta,10 alpha)-Isomer
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D003338 Corpus Luteum The yellow body derived from the ruptured OVARIAN FOLLICLE after OVULATION. The process of corpus luteum formation, LUTEINIZATION, is regulated by LUTEINIZING HORMONE. Corpora Lutea,Lutea, Corpora
D003341 Luteolysis Degradation of CORPUS LUTEUM. In the absence of pregnancy and diminishing trophic hormones, the corpus luteum undergoes luteolysis which is characterized by the involution and cessation of its endocrine function. Corpus Luteum Regression,Luteal Regression,Regression, Corpus Luteum,Regression, Luteal
D005260 Female Females
D005786 Gene Expression Regulation Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control (induction or repression) of gene action at the level of transcription or translation. Gene Action Regulation,Regulation of Gene Expression,Expression Regulation, Gene,Regulation, Gene Action,Regulation, Gene Expression

Related Publications

Antonio M Galvao, and David W Ramilo, and Dariusz J Skarzynski, and Karolina Lukasik, and Angela Tramontano, and Antonio Mollo, and Luisa M Mateus, and Graca Maria L Ferreira-Dias
March 2002, Biology of reproduction,
Antonio M Galvao, and David W Ramilo, and Dariusz J Skarzynski, and Karolina Lukasik, and Angela Tramontano, and Antonio Mollo, and Luisa M Mateus, and Graca Maria L Ferreira-Dias
April 2000, FEBS letters,
Antonio M Galvao, and David W Ramilo, and Dariusz J Skarzynski, and Karolina Lukasik, and Angela Tramontano, and Antonio Mollo, and Luisa M Mateus, and Graca Maria L Ferreira-Dias
June 1999, Biochemical and biophysical research communications,
Antonio M Galvao, and David W Ramilo, and Dariusz J Skarzynski, and Karolina Lukasik, and Angela Tramontano, and Antonio Mollo, and Luisa M Mateus, and Graca Maria L Ferreira-Dias
May 2015, Reproductive sciences (Thousand Oaks, Calif.),
Antonio M Galvao, and David W Ramilo, and Dariusz J Skarzynski, and Karolina Lukasik, and Angela Tramontano, and Antonio Mollo, and Luisa M Mateus, and Graca Maria L Ferreira-Dias
November 1998, Journal of immunology (Baltimore, Md. : 1950),
Antonio M Galvao, and David W Ramilo, and Dariusz J Skarzynski, and Karolina Lukasik, and Angela Tramontano, and Antonio Mollo, and Luisa M Mateus, and Graca Maria L Ferreira-Dias
April 1999, Biology of reproduction,
Antonio M Galvao, and David W Ramilo, and Dariusz J Skarzynski, and Karolina Lukasik, and Angela Tramontano, and Antonio Mollo, and Luisa M Mateus, and Graca Maria L Ferreira-Dias
September 1972, American journal of veterinary research,
Antonio M Galvao, and David W Ramilo, and Dariusz J Skarzynski, and Karolina Lukasik, and Angela Tramontano, and Antonio Mollo, and Luisa M Mateus, and Graca Maria L Ferreira-Dias
October 2014, Molecular human reproduction,
Antonio M Galvao, and David W Ramilo, and Dariusz J Skarzynski, and Karolina Lukasik, and Angela Tramontano, and Antonio Mollo, and Luisa M Mateus, and Graca Maria L Ferreira-Dias
August 1989, Canadian journal of physiology and pharmacology,
Antonio M Galvao, and David W Ramilo, and Dariusz J Skarzynski, and Karolina Lukasik, and Angela Tramontano, and Antonio Mollo, and Luisa M Mateus, and Graca Maria L Ferreira-Dias
May 2003, Journal of pharmacological sciences,
Copied contents to your clipboard!